Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096265 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 3
- Development phase
- 126
- Enrollment target
NCT00096265: Clinical Trial Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00096265 is a Phase 3 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 126 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096265, a Phase 3 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 126 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying whole-brain radiation therapy and stereotactic radiosurgery with or without temozolomide or erlotinib to see how well they work compared to whole-brain radiation therapy and stereotactic radiosurgery in treating patients with brain metastases secondary to non-small cell lung cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Stereotactic radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by blocking blood flow to the tumor. It is not yet known whether radiation therapy and stereotactic radiosurgery are more effective with or without temozolomide or erlotinib in treating brain metastases.
Interventions
- DRUG Temozolomide
- RADIATION Stereotactic Radiosurgery
- RADIATION 3-Dimensional Conformal Radiation Therapy
- DRUG Erlotinib Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2004-10-06 |
| Est. Completion | 2012-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096265
The ClinicalTrials.gov registry entry for NCT00096265 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT00096265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096265 about?
NCT00096265 is a clinical study titled "Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer". This randomized phase III trial is studying whole-brain radiation therapy and stereotactic radiosurgery with or without temozolomide or erlotinib to see how well they work compared to whole-brain radiation therapy and stereotactic radiosurgery in treating patients with brain metastases secondary to ...
What is the current status of trial NCT00096265?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 126 participants. The study started on 2004-10-06. Estimated completion is 2012-04-01.
What interventions are being tested in trial NCT00096265?
The interventions under investigation include: Temozolomide (DRUG), Stereotactic Radiosurgery (RADIATION), 3-Dimensional Conformal Radiation Therapy (RADIATION), Erlotinib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00096265?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.